Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vyome Holdings, IncOBLN · Entity 1824 | Director · President, CEO & Exec Chairman | June 23, 2020 | June 25, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vyome Holdings, Inc
Report date June 23, 2020 · Filed June 25, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Expires 2030-06-23 | Direct | 52,865 |
Reported balance
After 2020-06-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-06-23 · Grant · Acquired 52,865 · Balance 52,865 F1: Each share of Common Stock underlying the cash-settled Option represents the right to a cash payment equal to the excess, if any, of (i) the Fair Market Value of each such share on the date of exercise over (ii) the exercise price per share set forth in the Notice of Stock Option Grant ($0.73), and such Option shall vest as to 1/36th of the shares of Common Stock underlying the Option on each monthly anniversary of the grant date, subject to the Grantee's continued service with the Company through the applicable vesting date. This Option may not be exercised for Shares of the Company's Common Stock. F2: The Option shall vest as to 1/36th of the shares of Common Stock underlying the Option on each monthly anniversary of the grant date, subject to the Grantee's continued service with the Company through the applicable vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.73 · Expires 2030-06-23 | Direct | 165,135 |
Reported balance
After 2020-06-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-06-23 · Grant · Acquired 165,135 · Balance 165,135 F2: The Option shall vest as to 1/36th of the shares of Common Stock underlying the Option on each monthly anniversary of the grant date, subject to the Grantee's continued service with the Company through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Common Stock underlying the cash-settled Option represents the right to a cash payment equal to the excess, if any, of (i) the Fair Market Value of each such share on the date of exercise over (ii) the exercise price per share set forth in the Notice of Stock Option Grant ($0.73), and such Option shall vest as to 1/36th of the shares of Common Stock underlying the Option on each monthly anniversary of the grant date, subject to the Grantee's continued service with the Company through the applicable vesting date. This Option may not be exercised for Shares of the Company's Common Stock.
F2: The Option shall vest as to 1/36th of the shares of Common Stock underlying the Option on each monthly anniversary of the grant date, subject to the Grantee's continued service with the Company through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 23, 2020 Filed Jun 25, 2020 22:56 UTC | Vyome Holdings, Inc OBLN · Entity 1824 | GrantStock Option (Right to Buy) · Derivative | 165,135 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0001214659-20-005893 · marketforms-49131.xml · derivative · entry 2 Rasdal Andrew P · CIK 0001323238 · Director · President, CEO & Exec Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,135 Underlying: Common Stock · 165,135 shares Expires 2030-06-23 F2 · derivative.exercise_date: The Option shall vest as to 1/36th of the shares of Common Stock underlying the Option on each monthly anniversary of the grant date, subject to the Grantee's continued service with the Company through the applicable vesting date. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 22:56 UTC | Vyome Holdings, Inc OBLN · Entity 1824 | GrantStock Option · Derivative | 52,865 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-20-005893 · marketforms-49131.xml · derivative · entry 1 Rasdal Andrew P · CIK 0001323238 · Director · President, CEO & Exec Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,865 Underlying: Common Stock · 52,865 shares Expires 2030-06-23 F1 · derivative.exercise_price: Each share of Common Stock underlying the cash-settled Option represents the right to a cash payment equal to the excess, if any, of (i) the Fair Market Value of each such share on the date of exercise over (ii) the exercise price per share set forth in the Notice of Stock Option Grant ($0.73), and such Option shall vest as to 1/36th of the shares of Common Stock underlying the Option on each monthly anniversary of the grant date, subject to the Grantee's continued service with the Company through the applicable vesting date. This Option may not be exercised for Shares of the Company's Common Stock. F2 · derivative.exercise_date: The Option shall vest as to 1/36th of the shares of Common Stock underlying the Option on each monthly anniversary of the grant date, subject to the Grantee's continued service with the Company through the applicable vesting date. Read SEC document |
| August 06, 2019 Filed Aug 8, 2019 18:27 UTC | Vyome Holdings, Inc OBLN · Entity 1824 | PurchaseWarrants (Right to Buy) · Derivative | 9,375 | $0.00 Strike: $4.40 | $0.00 |
DisclosureSEC source: 0001214659-19-005089 · marketforms-45431.xml · derivative · entry 2 Rasdal Andrew P · CIK 0001323238 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,375 Underlying: Common Stock · 9,375 shares Expires 2024-08-06 Read SEC document |
| August 06, 2019 Filed Aug 8, 2019 18:27 UTC | Vyome Holdings, Inc OBLN · Entity 1824 | PurchaseCommon Stock | 12,500 | $4.00 | $50,000.00 |
DisclosureSEC source: 0001214659-19-005089 · marketforms-45431.xml · nonDerivative · entry 1 Rasdal Andrew P · CIK 0001323238 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,892 F1 · price: Reflects price paid to underwriters in Issuer's registered offering. F2 · balance_after: Includes Restricted Shares that are subject to vesting. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 23:29 UTC | Vyome Holdings, Inc OBLN · Entity 1824 | GrantCommon Stock (Restricted Stock Units) | 86,957 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-19-000146 · marketforms-43637.xml · nonDerivative · entry 1 Rasdal Andrew P · CIK 0001323238 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 653,905 F1 · shares: The award will vest in full on January 2, 2020, subject to Mr. Rasdal's continued service through such date. Read SEC document |
| August 23, 2018 Filed Aug 28, 2018 01:32 UTC | Vyome Holdings, Inc OBLN · Entity 1824 | GrantCommon Stock | 109,890 | $1.82 | $199,999.80 |
DisclosureSEC source: 0001214659-18-005736 · marketforms-42783.xml · nonDerivative · entry 1 Rasdal Andrew P · CIK 0001323238 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 566,948 F1 · shares: The reporting person purchased these shares directly from the issuer in a private placement. Read SEC document |
| April 30, 2018 Filed May 2, 2018 11:23 UTC | Vyome Holdings, Inc OBLN · Entity 1824 | GrantCommon Stock | 2,987 | $3.27 | $9,767.49 |
DisclosureSEC source: 0001214659-18-003245 · marketforms-41863.xml · nonDerivative · entry 1 Rasdal Andrew P · CIK 0001323238 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 457,058 F1 · kind: These shares were acquired under the Obalon Therapeutics, Inc. 2016 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 21:17 UTC | Vyome Holdings, Inc OBLN · Entity 1824 | GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $7.15 | $0.00 |
DisclosureSEC source: 0001214659-18-000192 · marketforms-40637.xml · derivative · entry 1 Rasdal Andrew P · CIK 0001323238 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2028-01-02 F1 · derivative.exercise_date: The Option shall vest as to 1/48th of the Shares underlying the Option on each monthly anniversary of the Grant Date, subject to the grantee's continued status as a Service Provider with the Company through the applicable vesting date. Read SEC document |
| October 31, 2017 Filed Nov 2, 2017 18:24 UTC | Vyome Holdings, Inc OBLN · Entity 1824 | GrantCommon Stock | 808 | $7.17 | $5,793.36 |
DisclosureSEC source: 0001214659-17-006344 · marketforms-40042.xml · nonDerivative · entry 1 Rasdal Andrew P · CIK 0001323238 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 454,071 F1 · kind: These shares were acquired under the Obalon Therapeutics, Inc. 2016 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| April 30, 2017 Filed May 2, 2017 22:51 UTC | Vyome Holdings, Inc OBLN · Entity 1824 | GrantCommon Stock | 2,768 | $9.03 | $24,995.04 |
DisclosureSEC source: 0001214659-17-002937 · marketforms-38714.xml · nonDerivative · entry 2 Rasdal Andrew P · CIK 0001323238 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 453,263 F1 · kind: These shares were acquired under the Obalon Therapeutics, Inc. 2016 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| November 09, 2016 Filed Nov 14, 2016 22:43 UTC | Vyome Holdings, Inc OBLN · Entity 1824 | GrantStock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $8.74 | $0.00 |
DisclosureSEC source: 0001209191-16-149826 · doc4.xml · derivative · entry 1 Rasdal Andrew P · CIK 0001323238 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2026-11-09 F1 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, commencing on December 9, 2016, with 100% of the total shares vested on November 9, 2020, subject to the reporting person's provision of service to the issuer as the issuer's chief executive officer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.